In:
Frontiers in Pharmacology, Frontiers Media SA, Vol. 13 ( 2022-8-29)
Abstract:
Objective: To compare the clinical efficacy and safety of SIX Traditional Chinese Patent Medicines (TCPM) recommended by guidelines in improving lipids for patients with prediabetes by network meta-analysis. Methods: Randomized controlled trials of 6 TCPM in the treatment of prediabetes were searched systematically in various databases. After extracting effective data, the risk of bias was assessed using Review Manager 5.3 and Cochrane Collaboration Systems Evaluator’s Manual. Network meta-analysis was performed using STATA 15.0 based on the frequency statistical model. The effect size and credibility of the evidence for the intervention were summarized based on a minimal contextualized framework. Results: A total of 27 studies involving 2,227 patients were included. Compared with lifestyle modification (LM), Shenqi + LM [SMD −0.49 (95% CI: −0.85, −0.12)] and Jinqi + LM [SMD −0.44 (95% CI: −0.81, −0.06)] showed statistically significant effect in lowering TG, Shenqi + LM [SMD −0.51 (95%CI: −0.86, −0.17)] and Jinqi + LM [SMD −0.44 (95%CI: −0.80, −0.08)] in lowering TC, Jinlida + LM [SMD −0.31 (95%CI: −0.59, −0.04)] in lowering LDL-C, Shenqi + LM [SMD 0.29 (95%CI: 0.06, 0.51)] and Jinqi + LM [SMD 0.16 (95%CI: 0.01, 0.31)] in increasing HDL-C. Conclusion: For patients with prediabetes, Traditional Chinese patent medicine Jinqi and Shenqi combined with lifestyle modification were associated with a significant reduction in TG and TC, while Shenqi + LM was among the most effective. Jinlida + LM was among the least effective. Systematic Review Registration: https://clinicaltrials.gov/ , identifier PROSPERO (CRD42021279332).
Type of Medium:
Online Resource
ISSN:
1663-9812
DOI:
10.3389/fphar.2022.942563
DOI:
10.3389/fphar.2022.942563.s001
DOI:
10.3389/fphar.2022.942563.s002
DOI:
10.3389/fphar.2022.942563.s003
DOI:
10.3389/fphar.2022.942563.s004
DOI:
10.3389/fphar.2022.942563.s005
DOI:
10.3389/fphar.2022.942563.s006
DOI:
10.3389/fphar.2022.942563.s007
DOI:
10.3389/fphar.2022.942563.s008
DOI:
10.3389/fphar.2022.942563.s009
DOI:
10.3389/fphar.2022.942563.s010
DOI:
10.3389/fphar.2022.942563.s011
DOI:
10.3389/fphar.2022.942563.s012
DOI:
10.3389/fphar.2022.942563.s013
DOI:
10.3389/fphar.2022.942563.s014
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2587355-6
SSG:
15,3
Permalink